China’s CFDA has sharply raised the fees it charges to review drugs and medical devices, a cost that drug companies are willing to pay if it means the agency will hire more reviewers and speed up the review process. The fee for a domestic innovative drug is now set at $100,637, a considerable jump from the $5,650 charged in 2013. At the end of 2014, the CFDA admitted that, despite numerous promises to shorten review times, the number of drugs awaiting approval had climbed to 18,500, up one-third over the year.
Help employers find you! Check out all the jobs and post your resume.
